Direct-targeting monoclonal antibodies (mAbs) approved for usage in oncology mainly belong to the immunoglobulin (Ig) G class currently. In fact, non-IgG therapeutic antibodies come of age with major progress in different kinds of human diseases, such as cancers and chronic inflammation. IgG mAb is no longer the only player in the therapeutic fields owing to antibody engineering technique, which is further driving the development of novel antibody formats. Besides, genetically modified cell-based therapies that harness the power of the immune system, together with non-IgG therapeutic antibodies, have improved cures in intractable human diseases. Learn more: IgE antibody engineering